Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.
Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML.
Faramand R, et al. Among authors: cao b.
Clin Cancer Res. 2020 Sep 15;26(18):4823-4831. doi: 10.1158/1078-0432.CCR-20-1434. Epub 2020 Jul 15.
Clin Cancer Res. 2020.
PMID: 32669372
Free PMC article.
Clinical Trial.